Adult -related myopathy carriers: Classification based on deep phenotyping.

Neurology

From the University of Rochester School of Medicine and Dentistry (B.T.C.), NY; Howard Hughes Medical Institute Janelia Research Campus (B.T.C., J.D.W.), Ashburn, VA; St Catharine's College (B.T.C.), University of Cambridge, UK; Clinical Center, NINDS (L.F.), Neuromuscular and Neurogenetic Disorders

Published: October 2019


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To better characterize adult myotubularin 1 ()-related myopathy carriers and recommend a phenotypic classification.

Methods: This cohort study was performed at the NIH Clinical Center. Participants were required to carry a confirmed mutation and were recruited via the Congenital Muscle Disease International Registry (n = 8), a traveling local clinic of the Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, NIH and Cure CMD (n = 1), and direct physician referral (n = 1). Neuromuscular examinations, muscle MRI, dynamic breathing MRI, cardiac MRI, pulmonary function tests (PFTs), physical therapy assessments including the Motor Function Measure 32 (MFM-32) scale, and X chromosome inactivation (XCI) studies were performed.

Results: Phenotypic categories were proposed based on ambulatory status and muscle weakness. Carriers were categorized as severe (nonambulatory; n = 1), moderate (minimal independent ambulation/assisted ambulation; n = 3), mild (independent ambulation but with evidence of muscle weakness; n = 4), and nonmanifesting (no evidence of muscle weakness; n = 2). Carriers with more severe muscle weakness exhibited greater degrees of respiratory insufficiency and abnormal signal on muscle imaging. Skeletal asymmetries were evident in both manifesting and nonmanifesting carriers. Skewed XCI did not explain phenotypic severity.

Conclusion: This work illustrates the phenotypic range of -related myopathy carriers in adulthood and recommends a phenotypic classification. This classification, defined by ambulatory status and muscle weakness, is supported by muscle MRI, PFT, and MFM-32 scale composite score findings, which may serve as markers of disease progression and outcome measures in future gene therapy or other clinical trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815204PMC
http://dx.doi.org/10.1212/WNL.0000000000008316DOI Listing

Publication Analysis

Top Keywords

muscle weakness
20
-related myopathy
12
myopathy carriers
12
muscle
9
muscle mri
8
mfm-32 scale
8
ambulatory status
8
status muscle
8
weakness carriers
8
evidence muscle
8

Similar Publications

This report presents the case of a 36-year-old man complaining of chronic low back pain and numbness along the posterolateral surface of the right leg. Magnetic resonance imaging (MRI) revealed a disc degeneration and protrusion at the L-S level and an extensive fluid-equivalent formation with a craniocaudal dimension of 8 cm at the S-S level. Initially, due to the minimal clinical complaints, the cyst was considered asymptomatic.

View Article and Find Full Text PDF

Long COVID-19 alters muscle architecture and muscle-tendon force transmission: a one-year longitudinal study.

Front Physiol

August 2025

Laboratory of Muscle and Tendon Plasticity, Graduate Program in Rehabilitation Science, Faculdade de Ciências e Tecnologias em Saúde, Universidade de Brasília, Brasília, Brazil.

Introduction: There are limited studies on the long-term effects of COVID-19 on skeletal muscle morphology and architecture. Therefore, this study aims to address this gap by assessing the effects of prior COVID-19 infection on quadriceps muscle architecture and tendon-aponeurosis complex (TAC) properties over a one-year period, comparing three cohorts: individuals with moderate COVID-19, individuals with severe COVID-19, and a healthy control group.

Methods: Seventy participants were included in the study and allocated to three groups: moderate COVID-19 (n = 22), severe COVID-19 (n = 18), and control (n = 30).

View Article and Find Full Text PDF

Background: Survivors of critical illness frequently face physical, cognitive and psychological impairments after intensive care. Sensorimotor impairments potentially have a negative impact on participation. However, comprehensive understanding of sensorimotor recovery and participation in survivors of critical illness is limited.

View Article and Find Full Text PDF

X-Linked Hypophosphatemia: Role of Fibroblast Growth Factor 23 on Human Skeletal Muscle-Derived Cells.

Calcif Tissue Int

September 2025

FirmoLab, Fondazione F.I.R.M.O. Onlus and Stabilimento Chimico Farmaceutico Militare (SCFM), 50141, Florence, Italy.

X-linked hypophosphatemia (XLH) is a rare and progressive disease, due to inactivating mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene. These pathogenic variants result in elevated circulating levels of fibroblast growth factor 23 (FGF23), responsible for the main clinical manifestations of XLH, such as hypophosphatemia, skeletal deformities, and mineralization defects. However, XLH also involves muscular disorders (muscle weakness, pain, reduced muscle density, peak strength, and power).

View Article and Find Full Text PDF

The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications.

Biomed Pharmacother

September 2025

Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address:

Immune-mediated necrotizing myopathy (IMNM) is an emerging and severe form of myositis. Most patients experience persistent muscle weakness or recurrent attacks within their lifetime. The previous view suggests that autoimmune and complement activation play a key role in muscle damage, and aggressive immunotherapy may benefit patients.

View Article and Find Full Text PDF